Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8987 USD | -1.17% | -1.46% | -34.84% |
26/04 | Bluebird bio Gets Nasdaq Notice for Late Filing of Annual Report | MT |
27/03 | Wells Fargo Trims Price Target on Bluebird Bio to $3 From $4, Maintains Equalweight Rating | MT |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company appears to be poorly valued given its net asset value.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-34.84% | 175M | C | ||
-1.90% | 104B | B+ | ||
+6.84% | 97.47B | B+ | ||
+5.71% | 22.25B | B | ||
-12.74% | 21.68B | B+ | ||
-9.70% | 18.2B | A- | ||
-39.98% | 17.02B | A- | ||
-10.46% | 16.36B | B | ||
+6.68% | 14.39B | C+ | ||
+35.58% | 12.37B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BLUE Stock
- Ratings bluebird bio, Inc.